Journal article
Risk of relapse phenotype recurrence in multiple sclerosis
T Kalincik, K Buzzard, V Jokubaitis, M Trojano, P Duquette, G Izquierdo, M Girard, A Lugaresi, P Grammond, F Grand'Maison, C Oreja-Guevara, C Boz, R Hupperts, T Petersen, G Giuliani, G Iuliano, J Lechner-Scott, M Barnett, R Bergamaschi, V Van Pesch Show all
Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2014
Abstract
Objectives: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of demographic and clinical features on this phenotype. Methods: Information about relapses was collected using MSBase, an international observational registry. Associations between relapse phenotypes and history of similar relapses or patient characteristics were tested with multivariable logistic regression models. Tendency of relapse phenotypes to recur sequentially was assessed with principal component analysis. Results: Among 14,969 eligible patients (89,949 patient-years), 49,279 phenotypically characterised relapses were recorded. Visual and brainstem relapses o..
View full abstractRelated Projects (2)
Grants
Awarded by Novartis
Funding Acknowledgements
The work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship (grant number 11-054) and NHMRC Early Career Fellowship (Clinical) to TK (grant number 1071124); NHMRC Career Development Award (Clinical) to HB (grant number 628856); NHMRC Project Grant (grant number 1032484); NHMRC Centre for Research Excellence (grant number 1001216) and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer-Schering, Sanofi-Aventis and BioCSL.